Fosamax May Cause Osteonecrosis of the Jaw and Femur Fractures

Fosamax (alendronate), manufactured by Merck & Co., is bisphosphonate drug used to treat osteoporosis that was approved by the Food and Drug Administration (FDA) in 1995.

Fosamax has been linked with the onset of a serious bone condition called osteonecrosis of the jaw (ONJ) or jaw bone death. ONJ involves the loss or breakdown of the jaw bone. Minor symptoms can include jaw pain or swelling, infections of the gum, loosening of teeth, poor healing of the gums, or numbing of the jaw.  Severe symptoms include disfigurement of the mouth and jaw, or complete death of the jaw bone.

Fosamax may also cause femur fractures in patients who take the drug for five years or longer. Although Fosamax is prescribed to strengthen bones, it actually may make bones more brittle when used for a long period of time. Women taking Fosamax have experienced femur fractures while performing relatively non-strenuous activities, such as descending stairs or engaging in low-stress exercises, with no apparent cause. Studies published in the Journal of Orthopedic Trauma and the Journal of Bone and Mineral Research both link Fosamax and all bisphosphonate drugs to a rare type of spontaneous fracture in the femur.

The FDA notified Merck & Co. of this problem in 2008. However, Merck waited 16 months to add the risk of femur fractures to its list of potential Fosamax side effects, potentially placing additional patients at risk.

The Plymale Law Firm is handling litigation related to these injuries nationwide.

If you or someone you love has been diagnosed with osteonecrosis of the jaw, or suffered a femur fracture after taking Fosamax, you should contact the Plymale Law Firm for a free consultation by filling out the form on this page or by calling us at (877) 328-767­­0.

Comments are closed.